A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)
2019 ◽
Vol 21
(5)
◽
pp. 665-675
◽
2007 ◽
Vol 153
(6)
◽
pp. 1074-1080
◽
2013 ◽
Vol 15
(11)
◽
pp. 1220-1227
◽
2017 ◽
Vol 6
(3)
◽
2018 ◽
Vol 122
(12)
◽
pp. 2166-2167